Keryx Biopharmaceuticals, Inc. Announces Pricing of $110

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

NEW YORK, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced the pricing of an underwritten public offering of common stock consisting of 9,166,667 shares at $12.00 per share, for gross proceeds of $110 million. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia™ (ferric citrate) in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.

J.P. Morgan Securities LLC is acting as sole book-running manager in the offering. The lead manager for the offering is Cowen and Company, LLC. Co-managers for the offering are Oppenheimer & Co. Inc.; JMP Securities LLC; Stifel, Nicolaus & Company, Incorporated; Mizuho Securities USA; Roth Capital Partners, LLC; Brean Capital, LLC; Ladenburg Thalmann & Co. Inc.; Maxim Group LLC; H.C. Wainwright & Co.; and MLV and Company LLC. Trout Capital LLC is acting as an advisor to the company.

The securities described above are being offered by Keryx pursuant to a Form S-3 shelf registration statement (including a base prospectus) previously filed with the Securities and Exchange Commission ("SEC"). Before you invest, you should read the prospectus in the registration statement and related prospectus supplement that Keryx has filed with the SEC for more complete information about Keryx and this offering. The prospectus supplement is available for free by visiting EDGAR on the SEC's website located at www.sec.gov . Copies of the prospectus supplement and accompanying prospectus may also be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone: 866-803-9204).

This news release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company launched its first FDA-approved product, Auryxia, in the United States in December 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com .

Cautionary Statement

Some of the statements included in this press release, particularly those regarding the commercialization and subsequent clinical development of Auryxia, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether Auryxia will be successfully launched and marketed in the U.S.; whether Riona® will be successfully marketed by our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd; the risk that the EMA may not concur with our interpretation of our registration studies in ESRD and non-dialysis dependent chronic kidney disease, supportive data, conduct of the studies, or any other part of our MAA submission and could ultimately deny approval of the MAA; the risk that we may not be successful in the development of ferric citrate for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT: Amy Sullivan, Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 94

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 13

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 156

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 111

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 69

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 205

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading

Top 5 Most Recently Viewed Articles

First Advantage to Engage Investors at Wolfe FinTech Forum

Updated Category News Views 219

First Advantage to Engage Investors at Wolfe FinTech Forum ATLANTA, March 04, 2025 — First Advantage Corporation (NASDAQ: FA), renowned as a premier provider in employment background screening, identity verification, and other related solutions, is set to showcase its offerings at an upcoming pivotal event. Management of First Advantage will participate in a fireside...

Continue Reading
European Markets Open Strong: EV Collaborations Boost Sentiment

Updated Category News Views 140

European Markets Show Positive Trends European stock markets are beginning the week on a high note, reflecting a cautiously optimistic mood among investors. The overall sentiment is driven by various factors that are currently in play within the financial landscape. The DAX in Germany has risen by 0.4%, while France's CAC 40 has increased by 0.7%. In contrast, the FTSE...

Continue Reading
Southern Company Stock Reaches New Heights, Driven by Growth

Updated Category News Views 81

Southern Company Achieves Record Stock Price Southern Company (NYSE: SO) has recently celebrated a remarkable achievement with its stock price hitting a record high of $91.87. This surge marks an impressive 36.84% increase over the past year, showcasing a growing optimism among investors in the energy sector. The company has been proactive in expanding its operations...

Continue Reading
Exploring GDP Trends: Navigating Economic Uncertainties

Updated Category News Views 337

Understanding Recent GDP Trends The latest economic indicators reveal complexities that question the idea of a resilient economy. Despite these challenges, we remain optimistic for the time being. Let's take a closer look at the current situation: GDP Growth Rate Adjustments The Atlanta Fed’s GDPNow tracking model recently revised its estimated growth rate for the first...

Continue Reading
Live Nation's Ticket Sales Surge Amid Mixed Earnings Report

Updated Category News Views 347

Overview of Live Nation's Recent Performance Live Nation Entertainment, Inc. (NYSE: LYV) witnessed a notable decline in its stock price after the announcement of third-quarter earnings that did not meet market expectations. Despite the drop, the company reported impressive ticket sales and revenue growth. Financial Highlights The entertainment giant reported a substantial...

Continue Reading